Biografía

Personal details:
- Dr. Bernardino Alcázar-Navarrete, PhD, MD.
- Actual work: Hospital Universitario Virgen de las Nieves. Granada

Professional Activity
- Medical Doctor. Universitiy of Granada.
- Respiratory Department. Hospital Universitario Virgen de las Nieves. Granada. Spain
- Associate Professor. Department of Medicine. University of Granada. Spain.

Previous appointments:
- 2002- 06: Respiratory training- Hospital Universitario Virgen de las Nieves. Granada.Spain
- 2006- 07: Internal Medicine. Hospital Val de Arán. Lleida. Spain
- 2007- 11: Respiratory Medicine. Complejo Hospitalario de Jaen. Jaén. Spain
- 2011- 2021: Hospital de Alta Resolución de Loja. Granada.
- 2021- : Hospital Universitario Virgen de las Nieves. Granada

Activities & felowships among Scientific Societies
- Chairman of the COPD Assembly of the Spanish Respiratory Society (SEPAR) (2012-
2015)
- Member of the Executive Committee of the Spanish Respiratory Society (SEPAR) (2012-
2015)
- Member of the Editorial Board of Archivos de Bronconeumologia & Open Respiratory Archives
- Member of the Respiratory Effectiveness Group.
Research skills:
- I have been granted by the Spanish Respiratory Society (SEPAR) and Spanish Goverment several times with successfull publications.
- I am included in several scientific research groups such as CIBERES.

CURRICULUM VITAE
- I have presented more than 30 abstracts in the last 5 years at international meeting such
as ATS, ERS and REG meetings.
- I have presented more than 20 lectures in the last 5 years at Spanish Respiratory Society
Meetings.
Most important Recently Published Papers
- Alcázar-Navarrete B, Ruiz Rodríguez O, Conde Baena P, Romero Palacios PJ, Agusti A. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J: 2018;51(1):1701457.
- Romero-Palacios PJ, Alcázar-Navarrete B, Díaz Mochón JJ, de Miguel-Pérez D, López Hidalgo JL, Garrido-Navas M del C, et al. Liquid biopsy beyond of cancer: Circulating pulmonary cells as biomarkers of COPD aggressivity. Crit Rev Oncol Hematol 2019;136:31–6.
- Feldman GJ, Sousa AR, Lipson DA, et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive
Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(11).
- Alcázar-Navarrete B, Castellano Miñán F, Santiago Díaz P, Ruiz Rodríguez O, Romero Palacios PJ. Óxido nítrico alveolar y bronquial en la enfermedad pulmonar obstructiva crónica y el
solapamiento de asma y EPOC (ACO). Arch Bronconeumol. 2018;54(8):414–9.
- Alcázar Navarrete B, Boucot I, Naya I, Tombs L, Lipson DA, Compton C, et al. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis. Pulm Ther.
2018; 20;1–13.
- Miravitlles, M., Monteagudo, M., Solntseva, I., & Alcázar, B. Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. Archivos de Bronconeumología, 2021;57(1), 13–20.
- Agusti A, Alcazar B, Cosio B, et al. Time for a change: anticipating the diagnosis and treatment of COPD. Eur Respir J. 2020;56(1):200210